

Repurposing of drugs for Covid-19: a systematic review and meta-analysis

Pinky Kotecha BSc¹; Alexander Light MBBS, BSc¹; Enrico Checcucci MD², Daniele Amparore MD², Cristian Fiori MD², Francesco Porpiglia MD²; Prokar Dasgupta MD, FRCS(Urol)^{1*}; Oussama Elhage MD, FRCS (Urol)¹

¹ Faculty of Life Science & Medicine, King's College London

² Department of Oncology, School of Medicine, University of Turin, San Luigi Hospital, Orbassano (Turin), Italy

*** Corresponding author:**

Prokar Dasgupta: Prokar.dasgupta@kcl.ac.uk

Peter Gorer Department of Immunobiology

School of Immunology and Microbial Sciences

NIHR Biomedical Research Centre - King's College London,

5th Floor Bermondsey Wing,

Guy's Hospital, London SE1 9RT

Tel: 0207 188 5906

Keywords: Public Health, Covid-19

Word count: 4968

Tables: 4

Figures: 6

Supplementary material: 1

Abstract

Objective: The aim of this systematic review is to evaluate the data currently available regarding the repurposing of different drugs for Covid-19 treatment. Participants with suspected or diagnosed Covid-19 will be included. The interventions being considered are drugs being repurposed, and comparators will include standard of care treatment or placebo.

Methods: We searched Ovid-MEDLINE, EMBASE, Cochrane library, clinical trial registration site in the UK(NIHR), Europe (clinicaltrialsregister.eu), US (ClinicalTrials.gov) and internationally (isrctn.com), and reviewed the reference lists of articles for eligible articles published up to April 22, 2020. All studies in English that evaluated the efficacy of the listed drugs were included. Cochrane RoB 2.0 and ROBINS-I tool were used to assess study quality. This systematic review adheres to the PRISMA guidelines. The protocol is available at PROSPERO (CRD42020180915).

Results: From 708 identified studies or clinical trials, 16 studies and 16 case reports met our eligibility criteria. Of these, 6 were randomized controlled trials (763 patients), 7 cohort studies (321 patients) and 3 case series (191 patients). Chloroquine (CQ) had a 100% discharge rate compared to 50% with lopinavir-ritonavir at day 14, however a trial has recommended against a high dosage due to cardiotoxic events. Hydroxychloroquine (HCQ) has shown no significant improvement in negative seroconversion rate which is also seen in our meta-analysis ($p=0.68$). Adverse events with HCQ have a significant

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

difference compared to the control group ($p=0.001$). Lopinavir-ritonavir has shown no improvement in time to clinical improvement which is seen in our meta-analyses ($p=0.1$). Remdesivir has shown no significant improvement in time to clinical improvement but this trial had insufficient power.

Discussion: Due to the paucity in evidence, it is difficult to establish the efficacy of these drugs in the treatment of Covid-19 as currently there is no significant clinical effectiveness of the repurposed drugs. Further large clinical trials are required to achieve more reliable findings. A risk-benefit analysis is required on an individual basis to weigh out the potential improvement in clinical outcome and viral load reduction compared to the risks of the adverse events. ⁽¹⁻¹⁶⁾

Introduction

Starting in December 2019, there was a pneumonia outbreak of unknown cause in Wuhan, Hubei province of China (17). The origin of the virus is unknown but there is an epidemiological link the Huanan Seafood Wholesale Market where there was a sale of wild animals, such as bats (17). After notification of the World Health Organisation (WHO) on 31 December 2019, scientists were able to isolate a 2019-nCoV from a patient and subsequently perform genome sequencing by the 7th of January. Since then many cases have emerged internationally leading to the WHO declaring the novel 2019-nCoV (Covid-19) outbreak a global pandemic (18).

Similar clinical features to previous betacoronavirus infections have been noted, including presentations with fever, dry cough and dyspnoea but very few presentations with prominent upper respiratory tract signs and symptoms such as rhinorrhoea, sneezing or sore throat (19). On imaging, bilateral ground-glass opacities on chest computed tomography (CT) scans have been noted. The patients with severe illness developed Acute Respiratory Distress Syndrome (ARDS) and required Intensive Care Unit (ICU) admission and oxygen therapy. These features bear resemblances with the severe acute respiratory distress syndrome (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. However, Covid-19 patients rarely develop intestinal symptoms such as diarrhoea which was present in about 20-25% of those with SARS-CoV and MERS-CoV. The mortality rate has been similarly described by cohorts (19-22) as 4-15%.

With many describing the memories of the novel coronavirus outbreak in China, SARS-CoV in 2003 (17), drugs used during SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) are being considered (19).

With no current universally agreed treatment for Covid-19, the current care advised is for supportive management depending on patient's needs, including antipyretics for fever and oxygen therapy.

The repurposing of drugs can provide an avenue to find treatment options for Covid-19 which has currently infected over 3.2 million people as of 2 May 2020 reported by the WHO (23).

Hydroxychloroquine (HCQ) and chloroquine (CQ), both anti-malarial drugs, have been authorised by both US and French authorities as there is no adequate approved and available alternative to treat Covid-19 (24). These drugs have been shown to have potent anti-viral activity against Covid-19 in in-vitro studies (25, 26). Both can have adverse effects with HCQ, a derivative of CQ, being less toxic when used long term. Therefore, recently, high-dosage of CQ (12g) with either azithromycin and oseltamir has not been recommended in patients with severe Covid-19 due to safety issues (27).

The use of anti-virals has also been trialled as previously, screening of approved drugs identified anti-virals to have an inhibitory activity on SARS-CoV. Lopinavir, an anti-viral, also has activity against MERS-CoV both in vitro and in animal models ¹⁴. Therefore, due to the homogeneity of SARS-CoV-2 compared to the mentioned zoonotic viruses, anti-virals which have previously been used are being repurposed. Remdesivir has also demonstrated

effective control of Covid-19 in-vitro (26) and has since been authorised for emergency use by the Food and Drug Administration (FDA) (28).

The aim of this systematic review is to evaluate the data currently available regarding the repurposing of different drugs for Covid-19 treatment.

Methods

Search strategy and selection criteria

This systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (29). We searched Ovid-MEDLINE, EMBASE, Cochrane library for articles published any time up to April 22, 2020. We also searched clinical trial registration sites in the UK (NIHR), Europe (clinicaltrialsregister.eu), US (ClinicalTrials.gov) and internationally (isrctn.com). We examined the reference lists of articles to identify additional studies.

The following search term was used: (favipiravir or remdesivir or galidesivir or ivermectin or oseltamivir or ganciclovir or lopinavir or ritonavir or darunavir or CQ or HCQ or arbidol or azithromycin or amoxicillin or moxifloxacin or ceftriaxone or antifungals or androgen receptor blockers or tea or traditional Chinese medicine) and ("2019 nCoV" or 2019nCoV or "2019 novel coronavirus" or "COVID 19" or COVID19 or "new coronavirus" or "novel coronavirus" or "SARS CoV-2" or (Wuhan coronavirus) or "COVID 19" or "SARS-CoV" or "2019-nCoV" or "SARS-CoV-2")

Only studies in English that evaluated the efficacy of the listed drugs were included. This included randomized controlled trials (RCTs) as well as observational studies (including cohort and control studies). Case reports were also collated.

Patients with suspected and consequently diagnosed with Novel coronavirus (Covid-19) will be included, with the following interventions: favipiravir, remdesivir, galidesivir, ivermectin, oseltamivir, ganciclovir, lopinavir/ ritonavir, darunavir, chloroquine, hydroxychloroquine, arbidol, azithromycin, amoxicillin, moxifloxacin, ceftriaxone, antifungals, androgen receptor blockers, tea and traditional Chinese medicine will be considered. Comparators will include standard of care treatment or placebo. The main outcomes will be time to clinical recovery, benefits in reducing mortality and reduction in viral load.

We excluded studies in other languages when no translation was available, review articles, commentaries and letters to editors.

One reviewer (PK) extracted data using a spreadsheet and a second (AL) validated data extraction. Descriptive and quantitative data were entered into a spreadsheet.

The protocol is available at PROSPERO (CRD42020180915).

Data analysis

One author (PK) extracted the data which was confirmed by another author (AL). Duplicate studies and clinical trials were removed as shown in PRISMA diagram (Figure 1).

Main summary measures

- Time to clinical recovery
- Benefits in reducing mortality
- Reduction in viral load
- Measures of effect as appropriate for the studies in question – hazards ratios, odds ratios and mean difference

Preplanned secondary outcomes included: Negative Seroconversion, time to a negative Covid-19 seroconversion, time to discharge, symptom alleviation, changes in blood tests, lung function, rate of respiratory failure, oxygen therapy requirement, non invasive ventilation requirement, radiological results, all cause mortality, rate of patients needing intensive care, Length of hospital stay, overall survival and adverse events.

Quality of studies (risk of bias) was assessed using the Cochrane RoB 2.0 for RCTs (Figure 2) and ROBINS-I (30) for non-RCTs (Figure 3).

Where trials examined similar outcomes and were considered suitably homogenous, meta-analysis was performed. For adverse events and rates of negative seroconversion, odds ratios with 95% confidence intervals were calculated. The chi squared test was used to assess for heterogeneity. If $p < 0.10$ for heterogeneity, then a random effects model was used, otherwise a fixed effects model was used. All meta-analyses were performed using the Cochrane Review Manager (v.5.3, 2014; Cochrane Initiative).

Results

Overview

Our literature search identified 937 studies or clinical trials, with 708 included after removal of duplicates. After abstract screening, 251 were included for full-text screening and of these 16 were included in qualitative synthesis (Figure 1), with 6 of these being randomized controlled trials.

Characteristics of studies (1-16) included are summarized in Table 1. 12 of the studies were carried out in China. The eligibility criteria varied, with some studies including any adult with Covid-19 while others restricted to mild, moderate or severe illness, defined differently by studies (summarised in Table 1). In total, from 16 studies, a total of 1275 patients were included in this systematic review. Of these, 141 received HCQ, 110 CQ, 91 HCQ + azithromycin, 283 Lopinavir-ritonavir (LPV-r), 171 arbidol, 16 arbidol and LPV/e, 151 favipavir, 53 remdesivir and 259 standard care. Standard care included, as necessary, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal replacement therapy, and extracorporeal membrane oxygenation (ECMO).

Primary outcome of the studies included are also variables including time to clinical recovery and viral clearance. Clinical improvement data for individual studies is summarized in Table 2. Data on Virology and Radiology is shown in Table 3.

Chloroquine (CQ)

2 studies examined the effects of CQ, 1 compared it to anti-viral treatment and 1 was a case series used in a news briefing. 1 study analysed both clinical recovery and viral clearance. CQ was initially mentioned in a news briefing (3), with results from more than 100 patients which had showed it was superior to the control treatment in shortening the disease course as well as inhibiting the exacerbation of pneumonia, improving lung imaging findings and promoting a virus negative conversion.

Subsequently, Huang et al. (5) compared it to another proposed therapy (LPV-r) in a cohort study with 10 patients in the CQ arm and 12 patients in the lopinavir/ritonavir arm. With CQ, 70% of the patients had a negative reverse transcriptase-polymerase chain reaction (RT-PCR) at day 7, 90% at day 10 and 100% at day 14. Compared to the LPV-r group where 58% of the patients had a negative RT-PCR at day 7, 75% at day 10 and 92% at day 14. There was a delay in lung clearance based on CT imaging, suggesting viral clearance does not translate immediately into pathological improvement in lungs. With CQ, 20% had a CT scan improvement at day 10 and 100% at day 14 compared to anti-virals with 8% showing an improvement at day 10 and 75% at day 14. With CQ, discharge rates from hospital were 100% at day 14 but with anti-virals, only 50% of the patients were discharged at day 14.

Hydroxychloroquine (HCQ)

6 studies examined the effects of HCQ, of which 2 also added azithromycin. 4 compared it to a standardized care and 2 were case series with HCQ and azithromycin. 4 studies analysed clinical recovery, whilst 6 studied viral clearance

There have been 3 RCTs in China. In the study by Chen et al. (1), where the eligibility criteria are not known, 30 patients were recruited, with 15 patients in each arm. It showed no significant difference ($p>0.05$) in negative seroconversion rate at day 7 with 87% negative in the HCQ group and 93% in the control group and in time to negative seroconversion ($p>0.05$). Time to normalization of body temperature was also comparable between the 2 arms and radiological progression using CT imaging showed 33% of the cases progressed of the HCQ group compared to 47% in the control group.

Chen et al. (2) has included only mild cases with oxygen saturation (SaO_2) $>93\%$ and confirmed chest CT with pneumonia, comparing HCQ ($n=31$) to standard treatment ($n=31$) which was undefined. The primary outcome was time to clinical recovery, defined as cough relief and return of body temperature ($<36.6^\circ\text{C}$ on surface, $<37.2^\circ\text{C}$ under armpit and mouth or $<37.8^\circ\text{C}$ in rectum and tympanic membrane) maintained for more than 72 hours. It was shown that normalization of body temperature was significantly ($p=0.0008$) shorter by 1 day in the HCQ group (2.2 days) compared to the control group (3.2 days). There was also significantly ($p=0.0016$) reduced cough remission time in the HCQ group (2 days) compared to the control group (3.1 days). It was also noted that overall 6% of the patients progressed to a severe illness and these occurred in the control group not receiving HCQ.

The largest randomized controlled trial (8) recruited a total of 150 patients enrolled from 16 centres, 75 in the HCQ arm and 75 in the standard of care (SOC) arm which included provision of intravenous fluids, supplemental oxygen, regulatory laboratory tests, SARS-CoV-

2 testing, haemodynamic monitoring and intensive care. This study included anyone over the age of 18 with a confirmed SARS-CoV-2 infection. The primary outcome was the negative conversion of SARS-CoV-2 within 28 days. Secondary outcomes included alleviation of clinical symptoms defined as resolving fever to axillary temperature of $<36.6^{\circ}\text{C}$, normalization of $\text{SaO}_2 > 94\%$ on room air, disappearance of respiratory symptoms; laboratory parameters and chest radiology within 28 days. Viral clearance was similar in both arms with a negative seroconversion rate at 28 days of 85.4% and 81.3% in the HCQ arm and SOC arm respectively. The time to negative seroconversion was also similar with 8 days and 7 days in HCQ and SOC arms respectively. The overall rate of symptom alleviation within 28 days was also similar with HCQ (59.9%) and with SOC alone (66.6%). The median time to alleviation of clinical symptoms was also similar with 19 days in the HCQ arm and 21 days in the SOC arm. However, in a subgroup analysis when confounding effects of other anti-viral agents was removed, the efficacy of HCQ on the alleviation of symptoms is more evident (Hazard ratio, 8.83, 95%CI, 1.09-71.3). Changes in c-reactive protein (CRP) and lymphocyte count were also analysed with the HCQ arm showing a significantly greater decline ($p=0.045$) in CRP from baseline (6.986) compared to the SOC arm (2.723) and a greater elevation in lymphocyte count from baseline in the HCQ (0.062) compared to SOC (0.008) which was not significant ($p=0.547$)

A French cohort study (7) enrolled 20 patients with HCQ and 16 patients was a control, regardless of their clinical status. It has shown that HCQ can provide clearing of nasopharyngeal carriage in 50% of the patients by day 3 compared to 6.3% without it. The same research group have reported a case series (4) with 80 patients on a combination of azithromycin and HCQ. This showed negative virus cultures in 97.5% of those included at day 5 with only 15% requiring oxygen and 4% requiring ICU. However, these results were rapidly questioned by another study (6) who followed the same regime of azithromycin and HCQ but showed that at day 5, 8 out of 10 (80%) of the patients were still positive for Covid-19 RNA.

Antivirals

A total of 8 studies regarding anti-virals was included, 6 studies examined the effects of LPV-r. Of these, 2 compared it to a standardized care, 1 compared it to favipavir, 1 compared it to the combination of LPV-r and arbidol, 1 compared it to arbidol and 1 compared it to both arbidol and a control group. 1 other study compared favipavir to arbidol and a case series regarding remdesivir is also included. 4 studies analysed clinical recovery, whilst 5 studied viral clearance.

There are 2 RCTs comparing LPV-r to control and one further compares it to arbidol. Cao et al. (14) is the largest RCT in this systematic review enrolling 199 patients with pneumonia confirmed by chest imaging, $\text{SaO}_2 < 94\%$ while on breathing ambient air, 99 in the LPV-r group and 100 to the standard-care group. The primary outcome was the time to clinical improvement, defined as time from randomization to improvement of two points on a seven category ordinal scale or live discharge which was 16 days in both LPV-r and standard-care alone. In subgroups of treatment within 12 days or later treatment, there was no association with a shorter time to clinical improvement. Secondary outcomes measured included a 28 day mortality which was lower in the LPV-r (19.2%) than in the standard-care

(25% group), stay in intensive care which was shorter in the LPV-r (6 days) group than in the standard-care (11 days) group, percentage of patients with clinical improvement at day 14 which was higher in the LPV-r group (45.5%) than in the standard-care group (30%) and time to discharge which was shorter in the LPV-r group (12 days) than in the standard-care group (14 days). Other secondary outcomes included duration of oxygen therapy, duration of hospitalization and time from randomization to death which had no significant difference between the two groups. In terms of virology, the percentage of patients with detectable viral RNA was similar in both groups on any sampling day (5, 10, 14, 21 and 28), for example at day 5, 34% in LPVr group compared to 32.9% in standard-care group. However, the mortality in this trial was 22.1% which is significantly higher than the mortality reported in descriptive studies, potentially indicating that a severely ill population was recruited. Therefore, the question of whether this anti-viral treatment may be effective in early treatment remains unaddressed.

Another RCT (11) recruiting patients with mild (mild symptoms but no signs of pneumonia on imaging) or moderate (fever, respiratory symptoms and pneumonia on imaging) Covid-19 compared LPV-r, arbidol and a control group with no anti-viral medication. The primary outcome was time of positive-to-negative conversion of SARS-CoV-2 from initiation of treatment to day 21 which was not significantly different ($p=0.981$). Time to viral clearance was 9 days, 9.1 days and 9.3 days in LPV-r, arbidol and control group respectively. There was also no significant difference of negative conversion rates at day 7 ($p=0.966$) and day 14 ($p=0.352$) of treatment. There was also no significant difference in secondary outcomes which included rate of antipyresis, rate of cough resolution and rate of improvement of chest CT imaging at day 7 and 14 ($p>0.05$). To take into account the influence of time from onset to treatment, this was evaluated in those who deteriorate to a severe clinical status (5 days) compared to those who did not deteriorate (4 days) and showed no significant difference ($p=0.619$).

However, one cohort study (9) comparing 42 patients treated with LPV-r to 5 patients in the control group has shown a significant reduction in time for body temperature normalization, 4.8 days in the LPV-r group compared to 7.3 days in the control group ($p=0.0364$).

In one study (12), LPV-r has also been used with arbidol which has higher negative seroconversion rate both at day 7 with 75% negative in the combination group compared to 35% in the LPV-r group ($p<0.05$) and at day 14, 94% negative in the combination group compared to 53% negative in the LPV-r group ($p<0.05$). There was also a significant difference ($p<0.05$) in the chest CT scans showing improvement in the combination group (69%) when compared to the LPV-r group (29%).

Another cohort study (15) has suggested favipavir is superior with a higher clinical recovery rate at day 7, defined as >72h recovery of body (axillary) temperature $<36.6^{\circ}\text{C}$, respiratory rate, SaO₂ >98% and cough relief (mild or none). This was significantly different ($p<0.0001$) with 61% of the patients clinically recovered in the favipavir group, compared to the 52% in the LPV-r group.

A case series (16) involving Remdesivir for compassionate use in 53 patients showed a 68% of the patients improved in the category of oxygen support by day 18 with 15% of the

patients worsening. The cumulative incidence of clinical improvement, defined by either a decrease of 2 or more points on the six point ordinal scale or live discharge, was 84% improvement. In this case series, 7 (13%) of the patients died, 6 of which were receiving non-invasive ventilation. Overall mortality from date of admission was 0.56 per 100 hospitalisation days and when comparing patients receiving invasive ventilation (0.57) to those receiving non invasive ventilation (0.51), there was no substantial difference. However, the risk of death was greater among patients over the age of 70 (hazard ratio 11.34) and those with a higher serum creatinine (hazard ratio 1.91).

Post-searching, a RCT done at 10 hospitals in Wuhan was published (31). This enrolled 237 patients who were Covid-19 positive, had pneumonia confirmed by chest imaging, had SaO₂<94% on room air and were within 12 days of symptoms onset, 158 to the remdesivir arm and 79 to the placebo arm. However, only 155 and 78 in the remdesivir and placebo arm respectively were included in the per-protocol population due to withdrawal of consent, receiving the medication for less days than the protocol and not starting the study. The primary clinical endpoint was time to clinical improvement defined as a two-point reduction in patients' admission status on a six-point scale. This was not significantly different in the remdesivir group (21 days) compared to the placebo group (23 days). In those receiving treatment within 10 days, there was a numerically faster time to clinical improvement in those in the remdesivir arm (18 days) compared to the placebo arm (23 days). Clinical improvement rates at day 7, 14 and day 28 were not significantly different between the remdesivir group and placebo group. However, numerically, at day 14 there was a higher clinical improvement rate at day 14 (27% with remdesivir compared to 23% in placebo) and at day 28 (65% with remdesivir compared to 58% in placebo). The 28 day mortality was similar between the remdesivir group (14%) and the placebo group (13%). Other clinical outcomes such as duration of oxygen support, duration of invasive mechanical ventilation duration of hospital stay, time to discharge and time to death were not significantly different. However, numerically, the days of invasive mechanical ventilation were lower in the remdesivir group (7 days) compared to the placebo group (15.5 days). In terms of viral load, no differences were observed between both groups with a similar decrease in viral load. In the same study, adverse events were reported in 66% of the patients (18% serious) in the remdesivir group, the most common ones being constipation, hypoalbuminaemia, hypokalaemia, anaemia, thrombocytopenia and increased total bilirubin. Adverse events were also reported in 64% (26% serious) of the patients in the control group, including hypoalbuminaemia, constipation, anaemia, hypokalaemia, increased aspartate aminotransferase, increased blood lipids and increased total bilirubin. Overall, more patients discontinued the drug due to adverse events in the remdesivir group (12%) than in the placebo group (5%).

Adverse events

Adverse events are summarized in Table 3. Adverse events relating to HCQ were reported in 3 studies with an average incidence of 21% (range 6-30), including symptoms of diarrhea, blurred vision, nausea, rash, headache and abnormal liver function tests. The adverse events of CQ were only reported in one study as 50% including vomiting, abdominal Pain, nausea, diarrhoea, rash, cough and dyspnea.

Antiviral side effects ranged from 0-60% across the studies with reported side effects such as liver injury (high transaminases, high bilirubin), leucopenia, gastro-intestinal and cutaneous side effects (diarrhea, vomiting, nausea, rash). One randomized controlled trial reported LPV-r adverse effects as 48% (19.2% serious ones) compared to 49% (32% serious ones) in the control group. The same study reported that 14% of the patients could not complete the 14 day course of LPV-r due to adverse events. There was only one case series regarding remdesivir which reported a 60% adverse event rate, including increased hepatic enzymes, renal impairment, diarrhea, rash and hypotension. This included 23% of severe adverse events including multiple organ dysfunction syndrome, septic shock, acute kidney injury and hypotension.

Case Reports

16 case reports (32-46) are summarised in Table 4. In each of the cases, a number of medications have been trialed, antibiotics in 10 of the cases, HCQ in 8, LPV-r in 7 and remdesivir in 2 of the cases. Interestingly, only 2 of them reported adverse effects, both with the use of HCQ and azithromycin: high transaminases, Atrial Fibrillation and long QT syndrome.

Risk of Bias

Figure 2 and 3 show the risk of bias assessment of each study, using RoB-2 for RCTs and ROBINS-I for non-RCTs. Of the 6 RCTs, 1 (1) was of high risk whilst 5 (11, 12, 14, 16) were of moderate risk. Of the non RCTs, 1 was not appropriate for analysis (15), 1 (13) was of moderate risk and 8 (4-7, 9, 10, 12, 16) were of serious risk.

Meta analysis

3 studies were included in the meta-analysis of adverse events using HCQ (Figure 4) and 2 studies were included in the meta-analysis of negative seroconversion rate using HCQ (Figure 5). In the meta-analysis of seroconversion rate, Cheng et al. measured this rate at day 7 while Tang et al. measured it at day 28. These show that there is a significant difference ($p=0.001$) regarding adverse events in HCQ compared to control group (Odds ratio 3.61, 95% CI, 1.66-7.84). However, no difference was found ($p=0.68$) in negative seroconversion rate between HCQ and the control group (Odds ratio 1.18, 95% CI, 0.53-2.66)

3 studies were included in the meta-analyses of adverse events with LPV-r (Figure 6). This shows that there is no significant difference ($p=0.1$) between LPV-r and control group regarding adverse events (Odds ratio 1.54, 95% CI, 0.92-2.55).

Discussion

Having been declared a global pandemic, with the numbers of cases rising everyday, Covid-19 has been an unprecedented challenge in a number of areas with a subsequent reorganization of the clinical activities (47). Clinicians across the world have trialed repurposing a number of medications. Regarding CQ, it has been suggested as a more effective and inexpensive option when compared to anti-virals (5). A recent trial (27) has compared the use of high-dosage (12g) and low-dosage CQ and has suggested that a high-dosage regimen with azithromycin and oseltamivir was not safe to continue due to concerns regarding cardiotoxic events, myocarditis and QTc interval prolongation which can be associated with an increase in fatal arrhythmias such as ventricular tachycardia. However, age can be a confounder as it can be associated with unfavourable outcomes. Therefore, it was advised that high dosage CQ should not be recommended in the treatment of severe Covid-19 but these findings cannot be extrapolated to patients with non-severe Covid-19.

The results from randomized controlled trials using HCQ have shown a similar negative seroconversion rate and time to clinical recovery, when compared to standard care. However, it has been recorded that HCQ may fasten normalization of body temperature and cough remission. With some smaller cohorts showing benefit of HCQ, it is important to be cautious with results. Therefore, overall, the role of HCQ in the management for Covid-19 may still remain promising but larger scale studies are required.

Anti-virals are another group of medications which have been investigated with both RCTs showing no difference when compared to standard-care alone. However, one RCT has shown that LPV-r may have a lower 28-day mortality, a shorter stay in intensive care, a shorter time to discharge and an effect on clinical improvement. The only study (16) regarding remdesivir identified in our search was an observational study about a compassionate use in patients with severe Covid-19, which showed an 84% clinical improvement and that improved in the category of oxygen support in 68% of the cases. After our search was carried out, a RCT (31) was published comparing remdesivir and placebo, showing no significant advantage in time to clinical improvement, mortality or time to viral clearance with remdesivir, even if well tolerated. However, the power of this study was insufficient as it did not reach its target enrolment, due to the marked reductions in new patient presentations in mid-March in Wuhan. The initiation of treatment might have been quite late in the disease course as there were restrictions on hospital bed availability to have a significant improvement in outcomes.

When summarizing the case reports, it is challenging to draw conclusions; however, the clinical improvement of the patients reported with a use of a cocktail of medications is an important aspect to consider.

The present systematic review has several limitations. The paucity of RCTs, the 'gold standard' for comparing interventions, is probably due to difficulties with randomization and blinding in the unprecedented and stressful environment faced by healthcare services. Therefore, a large number of studies are observational or cohort studies which are quicker to organize and implement, therefore obtaining results rapidly which is essential as the number of worldwide cases is rising at an alarming rate. Another limitation is that studies vary in the outcomes measured, therefore side-by-side comparisons become more difficult.

Due to this heterogeneity of the studies, we were only able to perform a meta-analysis on a maximum of 3 studies. In one of the analyses regarding negative seroconversion rate, they were measured at different time points, therefore not giving an accurate view. A large proportion of the studies included also do not measure survival and morbidity outcomes which are important. Many of the studies included have also not been formally peer reviewed yet but, due to the urgency of the pandemic, draft manuscripts have been uploaded.

We included every study found in our systematic review which may have introduced bias, therefore it is important to analyse all studies cautiously as the selection of patients is important as different studies have recruited patients with a different severity of Covid-19. It is also important to consider the timeline of the administration of the medication as early administration of medication could be more beneficial than later in the course of the disease. When using risk of bias assessment tools, most of the non-RCTs were at serious risk of bias due to confounders including baseline confounding factors such as the presence of comorbidities which could affect the outcome of the patient. No blinding of patients or assessors can also pose a risk of bias due to the potential unreliable measurement of outcomes.

To our knowledge, this is the first systematic review regarding the repurposing of drugs in Covid-19, summarizing 16 studies as well as 16 case reports. In conclusion, it is difficult to establish the efficacy of these drugs in the management of Covid-19 due to the lack of evidence. However, likewise, there is also no sufficient evidence to show these drugs are not successful in improving clinical outcomes and reducing viral load. Therefore, it is important to balance the benefits of trialing this medication with the adverse events described where the spectrum of these has not been clearly understood.

Accordingly, there is a need for further high quality data, especially from RCTs, to evaluate the benefits of these repurposed drugs in the treatment of patients with Covid-19. We recognise there is a large global effort for this, with the biggest Covid-19 trial, the RECOVERY trial (48), having recruited over 8500 participants across 173 sites to date (1 May 2020). This randomized trial is inviting clinically suspected or laboratory confirmed Covid-19 adult (>18 years) patients hospitalised in the United Kingdom to participate with randomisation to one of 4 arms: usual care, usual care plus LPV-r, usual care plus low-dose dexamethasone, usual care plus HCQ or usual care plus azithromycin. Those who deteriorate are further randomized between tocilizumab and a control group.

Conclusion

This study indicates no clinical effectiveness regarding the role of chloroquine, hydroxychloroquine and anti-viral for the treatment of Covid-19 patients. However, there is potential for these medications but further large clinical trials are required to achieve more reliable findings. Therefore, a risk-benefit analysis is required on an individual basis to weigh out the potential improvement in clinical outcome and viral load reduction compared to the risks of the adverse events.

Tables

Table 1: Characteristics of study (* - no dose reported, HCQ – hydroxychloroquine, LPV-r – lopinavir-ritonavir)

Author	Study Type	Country	Dates of study	Inclusion Criteria	Follow up period	Total number of patients	Number of patients in each arm	Age Median (IQR)	Male	Intervention	Outcomes
Hydroxychloroquine and chloroquine											
Chen et al. (1)	RCT	China	NR	NR	NR	30	15	NR	NR	HCQ 400mg OD for 5 days	Negative conversion rate of Covid-19 nucleic acid in respiratory pharyngeal swab on days 7
							15	NR	NR	Conventional treatment	

Chen et al. (2)	RCT	China	4 - 28 February 2020	Age ≥18 years with RT-PCR-confirmed Covid-19, CT-proven pneumonia, and mild illness (SaO2 >93%)	5 days	62	31	44.1 ± 16.1	14 (45.2%)	5 day HCQ 400mg/day	Time to clinical recovery (TTCR) - return of body temperature and cough relief, maintained for >72h- Body temperature <36.5°C on surface, <37.2°C under armpit and mouth or <37.8°C in rectum and tympanic membrane. Clinical characteristics. Radiological changes
							31	45.2 ± 15.3	15 (48.3%)	Control	
Gao et al. (3)	Case Series	China	NR	NR	NR	>100	N/A	NR	NR	Chloroquine Phosphate *	NR
Gautret et al. (4)	Case Series	France	3 to 21 March 2020	RT-PCR-confirmed Covid-19	At least 6 days	80	N/A	52 (18-88)	43 (53.8%)	HCQ and azithromycin *	Clinical outcome, contagiousness (PCT + culture), length of stay
Huang et al. (5)	Cohort	China	27 January to 15	Age ≥18 years with RT-PCR-confirmed Covid-19	14 days	22	10	41.5 (33.8–50.0)	7 (30%)	Chloroquine *	Real Time PCR for viral RNA, lung CT for improvement, length of stay (discharge

			February 2020				12	53.0 (41.8–63.5)	6 (50%)	LPV-r	criteria: temperature returned to <36.6°C in axilla for >3days, respiratory symptoms improved, pulmonary imaging showing absorption, detection of respiratory pathogenic nucleic acid negative twice in a row)
Molina et al. (6)	Case Series	France	NR	Hospitalised	5-6 days	11	N/A	58.7 (range 20-77)	7 (63.6%)	HCQ 600mg/day for 10 days and Azithromycin (500mg day1 and 250mg days2-5)	Viral clearance, clinical outcome
Gautret et al. (7)	Cohort	France	“Early” March to 16 March 2020	Age >12 years with RT-PCR-confirmed Covid-19	14 days	36	20	51.2 ± 18.7	9 (45%)	HCQ 200mg TDS 10 days	Viral clearance , clinical outcome
							16	37.3 ± 24.0	6 (37.5%)	Control	

Tang et al. (8)	RCT	China	11 - 29 February 2020	Age ≥18 years with RT-PCR-confirmed Covid-19	28 days	150	75	46	55%	HCQ 1200mg for 3 days. 800mg daily thereafter. Total duration - 2 or 3 weeks for mild/moderate or severe patients respectively	Negative seroconversion within 28-day, clinical outcome
							75				
Anti-virals											
Ye et al. (9)	Cohort	China	22 - 29 January	RT-PCR-confirmed Covid-19	10 days	47	42		21 (50%)	LVP 400mg- r 100mg BD	Body temperature, blood results
							5		1 (20%)	Control	
Zhu et al. (10)	Cohort	China	23 January - 29 February 2020	Covid-19 as diagnosed by the Chinese guideline	14 days	50	34	40.5 (34.8 – 52.3)	20 (58.8%)	LPV *- r*	RT-PCR, fever duration
							16	26.5 (23.3 – 52.5)	6 (37.5%)	Arbidol *	

Li et al. (11)	RCT	China	NR	Age 18-80 years with RT-PCR-confirmed Covid-19, which was mild (mild symptoms but no signs of pneumonia on imaging) or moderate (fever, respiratory symptoms and pneumonia on imaging)	14 days	86	34			LPV 200mg - r 50mg BD (500mg)	Average time of positive to negative conversion. Conversion rates at day 7 and 14, fever resolution, radiological changes, clinical outcome
							35			Arbidol 200mg TDS	
							17			No antiviral	
Deng et al. (12)	Cohort	China	17 January - 13 February 2020	Age ≥18 years with RT-PCR-confirmed Covid-19 pneumonia without invasive or non-invasive ventilation	14 days	33	16	41.8(14.08)	7 (43.8%)	Arbidol and LPV-r	Negative conversion rate, radiological changes
							17	47.25(17.25)	10 (58.8%)	LPV-r	
Cai et al. (13)	Cohort	China	30 January - 14 February 202	Age 16-75 years, RT-PCR-confirmed Covid-19 7 day duration from disease onset, not severe clinical condition (RR>30,	14 days	80	35	43 (35.5-59)	14 (40%)	Favipiravir day 1 1600mg BD, day 2-14 600mg BD	Time of viral clearance, radiological changes by Day 14

				SaO2<93%, respiratory failure, shock, multi-organ failure requiring ICU)			45	49 (36–61)	21 (46.7%)	Control, LPV- r 400mg/100mg BD	
Cao et al. (14)	RCT	China	18 January - 3 February 2020	Age ≥18 years with RT-PCR and radiologically-confirmed Covid-19 that was severe (SaO2<94% on room air or PaO2:FiO2 <300mgHg)	14 days	199	99 (94 received)	58 (49-68)	60.3%	LPV-e 400mg and 100mg PO BD	Time to clinical improvement: time from randomisation to an improvement of 2 points on a seven-category ordinal scale or live discharge from hospital
							100			Standard Care	
Chen et al. (15)	RCT	China	20 February - 1 March 2020	Age ≥18 years with evidence of Covid-19 clinically, radiologically, or lymphopenia	7 days	236	116	29 (25.00%) were ≥65 years	59 (50.86%)	Favipavir 1600mg BD/ first day, 600mg BD for 10 days	Clinical recovery rate at 7 days from beginning of treatment - >72h recovery of body (axillary) temperature <36.6°C, respiratory rate, SaO2 >98% and cough relief (mild or none)
							120	41 (34.17%) were ≥65 years	51 (42.5%)	Arbidol 200mg TDS	

Grein et al. (16)	Cohort	US, Europe, Canada, Japan	25 January - 30 March 2020	RT-PCR-confirmed Covid-19 with SaO2<94% on air or a need for oxygen support	28 days	53		64 (48-71)	40 (75%)	Remdesivir	Clinical improvement: live discharge from hospital or decrease of at least 2 points from baseline on modified ordinal six point scale
-------------------	--------	---------------------------	----------------------------	---	---------	----	--	------------	----------	------------	---

Table 2: Clinical Improvement (HCQ: hydroxychloroquine, LPV-r: Lopinavir-ritonavir)

Author	Intervention	Clinical Recovery	Median days for body temperature normalisation	O2 or NIV therapy	Duration of Invasive mechanical ventilation	ICU - rate of patients, length of stay	Length of stay in hospital	Time to discharge	Mortality
Hydroxychloroquine and chloroquine									
Chen et al. (1)	HCQ		1 (0-2)						
	Conventional treatment		1 (0-3)						
Chen et al. (2)	HCQ		3.2 (1.3)						
	Control		2.2 (0.4)						
Gautret et al. (4)	HCQ and azithromycin			O2: 12 (15%)		3 (3.8%)	4.6 ± 2.1 (1-11)	4.1 ± 4.2 (1-10)	1 (1.2%)
Huang et al. (5)	Chloroquine							By day 14: 100% discharged	
	LPV-r							By day 14: 50% discharged	
Molina et al. (6)	HCQ and azithromycin					2 (18.2%)			1 (9.1%)
Tang et al. (8)	HCQ	Median time to symptom alleviation: 19 days							

	Control	Median time to symptom alleviation: 21 days							
Anti-virals									
Ye et al. (9)	LPV-r		4.8 ± 1.94 days (p=0.0364)						
	Control		7.3 ± 1.53 days						
Cao et al. (14)	LPV-r	16 Day 7: 6 (6.1%) Day 14: 45 (45.4%) Day 28: 78 (78.8%)		O2 requirement: 12 (9-16)	4 (3-7)	Average stay in ICU - 6	14 (12-17)	12	28 day mortality: 19 (19.2%). 9 days to death (6-13)
	Standard Care	16 Day 7: 2 (2%) Day 14: 30 (30%) Day 28: 70 (70%)		O2 requirement - 13 (6-16) days	5 (3-9)	Average stay in ICU: 11	16 (13-18)	14	28 day mortality: 25 (25.0%). 12 days to death (6-15)
Chen et al. (15)	Favipavir	Day 7: 71 (61.2%)		O2 + NIV – 21 patients (18.1%)					0

	Arbidol	Day 7: 62 (51.7%)		O2 + NIV – 27 patients (22.5%)					0
Grein et al. (16)	Remdesivir	Day 28: 84% improvement		36 (68%) improvement in category of O2 support 8 (15%) worsening					0.56 deaths per 100 hospitalisation days. 7 (13%) deaths 15 days to death

Gautret et al. (4)	HCQ and azithromycin		Day 7: 83% negative Day 8: 93% negative	Day 5: 97.5% negative							5 Diarrhoea, 3 Nausea, 1 Blurred Vision
Huang et al. (5)	Chloroquine	Clearance by day 9: 6 (60%)			10 (100%)						50 (Vomiting, Abdominal Pain, Nausea, Diarrhoea, Rash or itchy, cough, dyspnoea)
	LPV-r	Clearance by day 9: 3 (25%)			11 (91.7%)						
Molina et al. (6)	HCQ and azithromycin							Day5-6, 8/10 (80%) positive RNA			

Gautret et al. (7)	HCQ		Day 3: 10 (50%) Day 4: 12 (60%) Day 5: 13 (65%) Day 14: 14 (70%)								
	Control		Day 3: 1 (6.3%) Day 4: 4 (25%) Day 5: 3 (18.8%) Day 6: 2 (12.5%)								
Tang et al. (8)	HCQ					85.4%	8		CRP decline 6.986 (p=0.045)		30 (Diarrhoea, Blurred vision)

	Control				81.3%	7		CRP decline 2.723	8.8
Anti-virals									
Ye et al. (9)	LPV-r					7.8 ± 3.09		First measurement: abnormal ALT in 9.5%, abnormal AST in 19% Third measurement: abnormal ALT in 22.7%, abnormal AST in 18.2%	
	Control					12 ± 0.82		25% ALT AST abnormal	
Zhu et al. (10)	LPV-r				55.9%			9% high ALT	3 Leucopenia
	Arbidol				50%			19% high ALT	13 Leucopenia

Li et al. (11)	LPV-r	Improvement at 14 days: 21 (75.0%)		12 (35.3%)	29 (85.3%)		9.0 ± 5.0			4.8% ALT elevation	35 (27 Diarrhoea, 12 Loss of appetite)
	Arbidol	Improvement at 14 days: 32 (91.4%)		13 (37.1%)	32 (91.4%)		9.1 ± 4.4				14 (9 Diarrhoea 6 Nausea)
	No antiviral	Improvement at 14 days: 13 (76.5%)		7 (41.2%)	12 (76.5%)		9.3 ± 5.2				0
Deng et al. (12)	Arbidol and LPV-r	Improvement at 7 days: 11 (69%)		12 (75%)	15 (94%)					Stool positive after treatment: 1	68.7 Elevated bilirubin, 43.7 Digestive upset
	LPV-r	Improvement at 7 days: 5 (29%)		6 (35%)	9 (53%)					Stool positive after treatment: 3	

Cai et al. (13)	Favipiravir	Improvement at 14 days: 32 (91.4%) Progression at 14 days: 1 (3.23%) No change at 14 days: 2 (6.45%)				4 (IQR 2.5-9)				11 (14 Diarrhoea, 7 Liver Injury, 7 Poor diet)
	LPV-r	Improvement at 14 days: 28 (62.2%) Progression at 14 days: 9 (20.0%) No change at 14 days: 8 (17.78%)				11 (IQR 8-13)				56 (13 Nausea, 11 Diarrhoea, 11 Vomiting, 9 Rash, 7 Liver Injury, 4 Chest tightness/ palpitations)

Cao et al. (14)	LPV-r							Day 5: 34.5% Day 10: 50% Day 14: 55.2% Day 21: 58.6% Day 28: 60.3%			48 (19.2 serious, 4 serious GI events)
	Standard Care							Day 5: 32.9% Day 10: 48.6% Day 14: 57.1% Day 21: 58.6% Day 28: 58.6%			50 (32 serious)
Chen et al. (15)	Favipavir										32 (13.8 Increased serum uric acid)
	Arbidol 200mg TDS										23 (2.5 Increased serum uric acid)

Gren et al. (16)	Remdesivir									60 (23 severe) (Increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. Of the severe, multiple organ dysfunction syndrome, septic shock, AKI, hypotension)
------------------	------------	--	--	--	--	--	--	--	--	---

Table 4: Case Reports

Author	Title	Age	Gender	Comorbidities	Medication given	Clinical improvement from admission	Adverse events
Cheng et al. (32)	First case of Coronavirus Disease 2019 (Covid-19) pneumonia in Taiwan	55	F	Hypothyroidism	Antibiotics - ceftriacone, amoxicillin/clavulanate	Day 27: oxygen therapy ceased Day 28: discharged	
Falcão et al. (33)	Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (Covid-19)	29	F	Recent childbirth post-partum haemorrhage	Azithromycin, Pepercaillin tazobactam, Hydroxychloroquine	Day 16: remained in ICU but clinically improving	High transaminases
Gabriels et al. (34)	Inpatient use of mobile continuous telemetry for Covid-19 patients treated with hydroxychloroquine and azithromycin	72	F	Paroxysmal atrial fibrillation	Hydroxychloroquine and azithromycin		AF, long QTc
Guilpain et al. (35)	Rituximab for granulomatosis with polyangiitis in the pandemic of Covid-19: lessons from a case with severe pneumonia	52	F	Granulomatosis with polyangiitis, overweight (BMI 27), hypertension	Lopinavir/ ritonavir for 3 days from Day12. Hydroxychloroquine for 10 days from	Day 20: extubated Day 25: oxygen therapy ceased Day 29: seronegative and discahrged	None reported

Han et al. (36)	The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019	M	F	Hypertension, type 2 diabetes, 20-year smoker	Lopinavir and ritonavir, methylprednisolone, recombinant human interferon alfa-2b, ambroxol hydrochloride, moxifloxacin hydrochloride	Day 10: discharged	
Hillaker et al. (37)	Delayed Initiation of Remdesivir in a COVID-19 Positive Patient	40	M	Anxiety, depression, obese (BMI 31), hypercholesterolaemia, 5-year smoker	Hydroxychloroquine 5 days, Remdesivir at day9	Day 12: extubated Day 13: oxygen therapy ceased	
Holshue et al. (38)	First Case of 2019 Novel Coronavirus in the United States	35	M	Hypertriglycercaemia	Vancomycin and cefepime. Day6 (day 10 illness), IV remdesivir	Day 8: oxygen therapy ceased	None reported
Kim et al. (39)	The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures	35	F	Obese (BMI 33)	Lopinavir/ ritonavir	Day 11: resolution of fever	None reported

Lim et al. (40)	Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of Covid-19 Pneumonia Monitored by Quantitative RT-PCR	54	M	None	Lopinavir/ ritonavir from day8	Day 9: resolution of fever	
Liu et al. (41)	A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan	52	F	Type 2 diabetes	Oseltamivir and levofloxacin on day3	Not reported	
Mathies et al. (42)	A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant	77	M	Heart transplant in 2003 (ischaemic cardiomyopathy), previous CMV-colitis and pneumonia, chronic kidney disease, hypertension, type 2 diabetes	Hydroxychloroquine and piperacillin/tazobactam and ganciclovir (Hx of CMV infections)	Day 7: oxygen therapy ceased Day 12: discharged	
Ning et al. (43)	Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report	29	M	Renal transplant in 2018 (chronic kidney disease), hypertension	Moxifloxacin, Trimethoprim, sulfamethoxazole. On day2, lopinavir/ritonavir. Antibacterial stopped.	Day 13: discharged	

Song et al. (44)	Coronavirus Disease 19 (Covid-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs	61	F	Rheumatoid arthritis	Lopinavir/ritonavir, regular medication - hydroxychloroquine, meloxicam and famotidine	Day24: discharged	
Spezzani et al. (45)	Benign Covid-19 in an immunocompromised cancer patient – the case of a married couple	60	F	Metastatic breast cancer (chemotherapy-treated), colonic angiodysplasia, bicuspid aortic valve, lower limb varicosities	Levofloxacin, piperacillin/tazobactam, darunavir/ cobicistat, hydroxychloroquine	Day 6: discharged	
		60	M (husband)	Hypertension	Darunavir/cobicistat and hydroxychloroquine and ceftriaxone, azithromycin	Day 11: extubated Day 23: discharged	
Tang et al. (46)	Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	50s	M	Renal failure (receiving haemodialysis), diabetes, hypertension, chronic hepatitis B	Moxifloxacin and lopinavir/ ritonavir	Day 8: discharged	

Figures




Figure 1: PRISMA diagram – study selection (29)

Figure 2: Risk of Bias for Randomised Controlled Trials using RoB 2.0 tool



Figure 3: Risk of Bias Assessment for Non-randomised Controlled trials using ROBINS-I tool (30)

	Bias due to confounding	Bias in selection of participants	Bias in classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measures of outcomes	Bias in selection of reported result	Overall
Gao et al.	Communication letter							
Gautret et al.	Serious	Moderate	Low	Low	Low	Moderate	Moderate	Serious
Huang et al.	Serious	Low	Low	Low	Low	Moderate	Moderate	Serious
Molina et al.	Serious	Moderate	Moderate	Low	Low	Low	Moderate	Serious
Gautret et al.	Serious	Low	Low	Low	Low	Moderate	Moderate	Serious
Ye et al.	Serious	Low	Low	Low	Moderate	Moderate	Low	Serious
Zhu et al.	Serious	Low	Low	Low	Low	Moderate	Low	Serious
Deng et al.	Serious	Low	Low	Low	Low	Moderate	Low	Serious
Cai et al.	Moderate	Low	low	Low	Low	Low	Low	Moderate
Grein et al.	Serious	Low	low	Low	Moderate	Moderate	Low	Serious

Figure 4: Effect of HCQ compared to control group on adverse events




Figure 5: Effect of HCQ compared to control group on negative seroconversion rate





Figure 6: Effect of Lopinavir-ritonavir compared to control group on adverse events



Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions

All authors contributed to the planning, conduct and reporting of the work. All authors approved the submitted version

Acknowledgements

None

Funding

There was no funding for this systematic review.

References

1. CHEN Jun LD, LIU Li, LIU Ping, XU Qingnian, XIA Lu, LING Yun, HUANG Dan, SONG Shuli, ZHANG Dandan, QIAN Zhiping, LI Tao, SHEN Yinzong, LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). *J Zhejiang Univ (Med Sci)*. 2020;49(1):0-.
2. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv*. 2020:2020.03.22.20040758.
3. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *BioScience Trends*. 2020;14(1):72-3.
4. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel medicine and infectious disease*. 2020:101663.
5. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. *Journal of molecular cell biology*. 2020.
6. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarne D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Medecine et maladies infectieuses*. 2020.
7. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents*. 2020:105949.
8. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. *medRxiv*. 2020:2020.04.10.20060558.
9. Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. *European review for medical and pharmacological sciences*. 2020;24(6):3390-6.
10. Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. *The Journal of infection*. 2020.
11. Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). *medRxiv*. 2020:2020.03.19.20038984.
12. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. *The Journal of infection*. 2020.
13. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*. 2020.
14. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine*. 2020.
15. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv*. 2020:2020.03.17.20037432.
16. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *The New England journal of medicine*. 2020.

17. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis.* 2020;91:264-6.
18. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Bio Medica Atenei Parmensis.* 2020;91(1):157-60.
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet.* 2020;395(10223):497-506.
20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet.* 2020;395(10223):507-13.
21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020.
22. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020.
23. World Health Organisation, 202. WHO COVID-19 Dashboard. Accessed 2 May 2020, <https://covid19.who.int/> [
24. Jaffe S. Regulators split on antimalarials for COVID-19. *The Lancet.* 2020;395(10231):1179.
25. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* 2020.
26. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(3):269-71.
27. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Network Open.* 2020;3(4):e208857-e.
28. US Food Drug and Administration (FDA), 2020. Accessed 2 May 2020, <https://www.fda.gov/media/137564/download> [
29. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* 2009;339:b2535.
30. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.* 2016;355:i4919.
31. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet.*
32. Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH, et al. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan. *J Formos Med Assoc.* 2020;119(3):747-51.
33. Falcao MB, Pamplona de Goes Cavalcanti L, Figueiras Filho NM, Antunes de Brito CA. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19). *The American journal of tropical medicine and hygiene.* 2020.

34. Gabriels J, Saleh M, Chang D, Epstein LM. Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. *HeartRhythm Case Reports*. 2020.
35. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. *Annals of the rheumatic diseases*. 2020.
36. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. *Journal of Medical Virology*. 2020;92(5):461-3.
37. Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed Initiation of Remdesivir in a COVID-19 Positive Patient. *Pharmacotherapy*. 2020.
38. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *New England Journal of Medicine*. 2020;382(10):929-36.
39. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. *Journal of Korean medical science*. 2020;35(5):e61-e.
40. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. *Journal of Korean medical science*. 2020;35(6):e79.
41. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A locally transmitted case of SARS-CoV-2 infection in Taiwan. *New England Journal of Medicine*. 2020;382(11):NEJMc2001573.
42. Mathies D, Rauschnig D, Wagner U, Mueller F, Maibaum M, Binnemann C, et al. A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
43. Ning L, Liu L, Li W, Liu H, Wang J, Yao Z, et al. Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020.
44. Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, et al. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. *Rheumatology international*. 2020.
45. Spezzani V, Piunno A, Iselin HU. Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple. *Swiss medical weekly*. 2020;150:w20246.
46. Tang B, Li S, Xiong Y, Tian M, Yu J, Xu L, et al. Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient. *Kidney medicine*. 2020.
47. Campi R, Amparore D, Capitanio U, Checcucci E, Salonia A, Fiori C, et al. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. *European Urology*.
48. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus) ISRCTN50189673 2020 [